Christine Marie Utter - 18 Jan 2022 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role: SVP, Finance & CAO
Signature: /s/ Avraham S. Adler, attorney-in-fact
Issuer symbol: PTCT
Transactions as of: 18 Jan 2022
Net transactions value: -$502,118
Form type: 4
Filing time: 20 Jan 2022, 15:50:35 UTC
Previous filing: 11 Jan 2022
Next filing: 03 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PTCT	Common Stock	Sale	$62,118	-1,428	-5.1%	$43.50	26,425	18 Jan 2022	Direct	F1
transaction	PTCT	Common Stock	Options Exercise	$180,100	+10,000	+38%	$18.01	36,425	18 Jan 2022	Direct	F1
transaction	PTCT	Common Stock	Sale	$440,000	-10,000	-27%	$44.00	26,425	18 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PTCT	Stock Option (Right to Buy)	Options Exercise	$180,100	-10,000	-100%	$18.01	0	18 Jan 2022	Common Stock	10,000	$18.01	Direct	F1, F2
holding	PTCT	Stock Option (Right to Buy)						4,688	18 Jan 2022	Common Stock	4,688	$40.45	Direct	F2
holding	PTCT	Stock Option (Right to Buy)						17,800	18 Jan 2022	Common Stock	17,800	$51.00	Direct	F2
holding	PTCT	Stock Option (Right to Buy)						21,250	18 Jan 2022	Common Stock	21,250	$33.02	Direct	F3
holding	PTCT	Stock Option (Right to Buy)						10,100	18 Jan 2022	Common Stock	10,100	$33.02	Direct	F4
holding	PTCT	Stock Option (Right to Buy)						23,800	18 Jan 2022	Common Stock	23,800	$51.16	Direct	F5
holding	PTCT	Stock Option (Right to Buy)						50,750	18 Jan 2022	Common Stock	50,750	$66.49	Direct	F6
holding	PTCT	Stock Option (Right to Buy)						43,500	18 Jan 2022	Common Stock	43,500	$38.10	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 14, 2021.
F2	Currently exercisable.
F3	This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F4	This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
F5	This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
F6	Represents an option award of 33,250 options and an option award of 17,500 options. These option awards were each granted on January 6, 2021, and each vests over four years, with 25% ofthe shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-monthperiod thereafter, beginning on April 6, 2022.
F7	This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.